Shanghai Bao Pharmaceuticals Co., Ltd. (HKG:2659)
Hong Kong · Delayed Price · Currency is HKD 14.31
-0.59 (-3.96%)
Sep 11, 2026, 4:08 PM HKT
HKG:2659 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
| 17.04 | 49.16 | 6.16 | 6.93 | |
Revenue Growth | -63.48% | 697.99% | -11.11% | - |
Cost of Revenue | 5.68 | 5.41 | 1.14 | 0.15 |
Gross Profit | 11.36 | 43.75 | 5.02 | 6.78 |
Selling, General & Admin | 101.46 | 108.13 | 113.43 | 47.58 |
Research & Development | 229.77 | 248.24 | 250.73 | 132.55 |
Other Operating Expenses | -22.22 | -3.59 | 0.35 | -6.68 |
Operating Expenses | 309.02 | 352.79 | 364.51 | 173.45 |
Operating Income | -297.65 | -309.04 | -359.49 | -166.66 |
Interest Expense | -6.4 | -5.97 | -4.56 | -3.66 |
Interest & Investment Income | 12.01 | 6.14 | 4.65 | 7.9 |
Earnings From Equity Investments | -0.18 | -0.24 | -0.61 | -0.92 |
Currency Exchange Gain (Loss) | -7.47 | -7.47 | 1.19 | 2.97 |
Other Non Operating Income (Expenses) | -12.76 | -25.19 | -5.57 | - |
EBT Excluding Unusual Items | -312.44 | -341.77 | -364.38 | -160.37 |
Gain (Loss) on Sale of Investments | 3.3 | 3.22 | - | - |
Gain (Loss) on Sale of Assets | 0.01 | 0.01 | -0.08 | -0.03 |
Legal Settlements | -56.76 | -56.76 | - | - |
Pretax Income | -365.89 | -395.3 | -364.46 | -160.4 |
Income Tax Expense | - | - | -0.02 | -0 |
Net Income | -365.89 | -395.3 | -364.43 | -160.4 |
Net Income to Common | -365.89 | -395.3 | -364.43 | -160.4 |
Net Income Growth | - | - | - | - |
Shares Outstanding (Basic) | 309 | 290 | 268 | 253 |
Shares Outstanding (Diluted) | 309 | 290 | 268 | 253 |
Shares Change | 9.81% | 8.43% | 5.82% | - |
EPS (Basic) | -1.18 | -1.36 | -1.36 | -0.63 |
EPS (Diluted) | -1.18 | -1.36 | -1.36 | -0.63 |
EPS Growth | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
Free Cash Flow | -472.2 | -333.41 | -338.06 | -276.58 |
Free Cash Flow Per Share | -1.53 | -1.15 | -1.26 | -1.09 |
Gross Margin | 66.69% | 89.00% | 81.49% | 97.85% |
Operating Margin | -1746.68% | -628.68% | -5835.80% | -2404.96% |
Profit Margin | -2147.12% | -804.18% | -5916.12% | -2314.50% |
Free Cash Flow Margin | -2770.96% | -678.27% | -5487.91% | -3991.02% |
EBITDA | -260.63 | -274.64 | -329.76 | -146.12 |
D&A For EBITDA | 37.03 | 34.4 | 29.73 | 20.55 |
EBIT | -297.65 | -309.04 | -359.49 | -166.66 |